Ulipristal

Generic Name
Ulipristal
Brand Names
Ella, Ellaone, Esmya, ellaOne
Drug Type
Small Molecule
Chemical Formula
C28H35NO3
CAS Number
159811-51-5
Unique Ingredient Identifier
6J5J15Q2X8
Background

Ulipristal is a selective progesterone receptor modulator used for the purposes of emergency contraception (Ella) and for the treatment of uterine fibroids (Fibristal). It is a derivative of 19-norprogesterone and has both antagonistic and partial agonist activity at the progesterone receptor. It also binds to glucocorticoid receptor, however compared to mif...

Indication

As the product Ella (available in Canada and the US), ulipristal is indicated for use as emergency contraception after unprotected intercourse or possible contraceptive failure when administered within 120 hours (5 days) after unprotected intercourse or a known or suspected contraceptive failure. As the product Fibristal (available in Canada), ulipristal is ...

Associated Conditions
Moderate Uterine Fibroids, Severe Uterine Fibroids
Associated Therapies
Emergency Contraception
Clinical Trials
Related News

Levonorgestrel-piroxicam Versus Ulipristal Acetate for Emergency Contraception

First Posted Date
2024-12-11
Last Posted Date
2024-12-11
Lead Sponsor
The University of Hong Kong
Target Recruit Count
980
Registration Number
NCT06727734

Disparities in Emergency Contraceptive Metabolism Dictate Efficacy

Phase 4
Recruiting
Conditions
Contraceptive Usage
Interventions
Drug: Ulipristal acetate
First Posted Date
2023-01-06
Last Posted Date
2024-08-19
Lead Sponsor
Oregon Health and Science University
Target Recruit Count
140
Registration Number
NCT05674513
Locations
🇺🇸

OHSU, Portland, Oregon, United States

Advance Provision of Postpartum Emergency Contraception and Its Effects on Reproductive Autonomy

First Posted Date
2022-03-17
Last Posted Date
2023-05-23
Lead Sponsor
Northwestern University
Target Recruit Count
75
Registration Number
NCT05285605
Locations
🇺🇸

Northwestern Medicine Prentice Women's Hospital, Chicago, Illinois, United States

Use of Ulipristal Acetate in Induction of Second Trimester Missed Abortion

First Posted Date
2021-08-04
Last Posted Date
2021-08-04
Lead Sponsor
Ain Shams University
Target Recruit Count
24
Registration Number
NCT04989400
Locations
🇪🇬

Ain SHams Maternity Hospital, Cairo, Abbaseya, Egypt

Liver Safety Assessment During Ulipristal Acetate Treatment for Uterine Fibroids (LISA)

First Posted Date
2019-07-02
Last Posted Date
2024-05-20
Lead Sponsor
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Target Recruit Count
30
Registration Number
NCT04004884
Locations
🇪🇸

Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

Ulipristal Acetate for Cervical Preparation

Early Phase 1
Completed
Conditions
Termination of Pregnancy
Interventions
Drug: Ulipristal Acetate
First Posted Date
2019-01-14
Last Posted Date
2020-07-01
Lead Sponsor
Stanford University
Target Recruit Count
13
Registration Number
NCT03802149
Locations
🇺🇸

Stanford Health Care, Stanford, California, United States

Study Comparing Emergency Contraception Effectiveness in Women Who Weight ≥ 80 kg

First Posted Date
2018-05-25
Last Posted Date
2019-10-08
Lead Sponsor
Health Decisions
Target Recruit Count
1200
Registration Number
NCT03537768
Locations
🇺🇸

Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States

🇺🇸

University of Pittsburgh/Magee Women's Hospital, Pittsburgh, Pennsylvania, United States

🇺🇸

Oregon Health Science University, Portland, Oregon, United States

and more 15 locations

Impact of Esmya on Fertility to Infertile Women With Fibroids Managed With Assisted Reproduction Techniques

First Posted Date
2017-11-21
Last Posted Date
2019-01-09
Lead Sponsor
ASSOCIATION POUR LE DEVELOPPEMENT EN FECONDATION IN VITRO
Target Recruit Count
127
Registration Number
NCT03349190
Locations
🇫🇷

Chu Angers, Angers, France

🇫🇷

Centre Hospitalier Intercommunal Creteil, Créteil, France

🇫🇷

Chu Dijon, Dijon, France

and more 20 locations

Mode of Action Study of Vilaprisan and Ulipristal Acetate in Patients With Uterine Fibroids for Whom Surgery is Planned

Phase 1
Terminated
Conditions
Leiomyoma
Interventions
Drug: Vilaprisan, BAY1002670
Drug: Ulipristal
First Posted Date
2017-11-17
Last Posted Date
2021-01-06
Lead Sponsor
Bayer
Target Recruit Count
10
Registration Number
NCT03342859
Locations
🇬🇧

Edinburgh Royal Infirmary/ NHS Lothian, Edinburgh, United Kingdom

Effect of Ulipristal Acetate on Bleeding Patterns and Dysmenorrhea in Women With Adenomyosis

First Posted Date
2017-10-30
Last Posted Date
2018-02-08
Lead Sponsor
Vanderbilt University Medical Center
Registration Number
NCT03325868
Locations
🇺🇸

Vanderbilt University Medical Center, Nashville, Tennessee, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy